HOOKIPA Pharma Inc. (HOOK)
NASDAQ: HOOK · IEX Real-Time Price · USD
0.582
-0.047 (-7.43%)
At close: Jul 2, 2024, 4:00 PM
0.589
+0.007 (1.24%)
After-hours: Jul 2, 2024, 7:56 PM EDT

HOOKIPA Pharma Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year
20232022202120202019 2018 - 2017
Cash & Equivalents
117.1113.0366.49142.74113.15
Upgrade
Cash & Cash Equivalents
117.1113.0366.49142.74113.15
Upgrade
Cash Growth
3.60%70.00%-53.42%26.15%132.92%
Upgrade
Receivables
19.2722.0121.1720.669.73
Upgrade
Other Current Assets
10.7512.1614.488.15.14
Upgrade
Total Current Assets
147.12147.2102.14171.5128.02
Upgrade
Property, Plant & Equipment
13.2221.9822.1213.9714.6
Upgrade
Long-Term Investments
0.430.420.430.430.42
Upgrade
Other Long-Term Assets
0.580.861.371.910.7
Upgrade
Total Long-Term Assets
14.2223.2623.9116.3115.73
Upgrade
Total Assets
161.34170.45126.05187.82143.75
Upgrade
Accounts Payable
12.55.498.768.010.94
Upgrade
Deferred Revenue
34.3141.355.564.533.66
Upgrade
Current Debt
2.763.284.4721.81
Upgrade
Other Current Liabilities
-7.57-14.498.866.68.33
Upgrade
Total Current Liabilities
41.9935.6327.6521.1414.76
Upgrade
Long-Term Debt
3.83.226.138.368.79
Upgrade
Other Long-Term Liabilities
25.6929.082.672.22.31
Upgrade
Total Long-Term Liabilities
29.4932.318.810.5511.09
Upgrade
Total Liabilities
71.4867.9436.4531.6925.85
Upgrade
Total Debt
6.566.510.610.3510.6
Upgrade
Debt Growth
0.86%-38.67%2.41%-2.31%141.33%
Upgrade
Retained Earnings
-369.26-287.68-222.77-147.1-103.02
Upgrade
Comprehensive Income
-7.93-7.16-4.78-6.07-4.65
Upgrade
Shareholders' Equity
89.86102.5289.59156.12117.9
Upgrade
Net Cash / Debt
110.54106.5255.88132.39102.55
Upgrade
Net Cash / Debt Growth
3.77%90.62%-57.79%29.09%132.08%
Upgrade
Net Cash Per Share
----5.74
Upgrade
Working Capital
105.13111.5674.48150.36113.26
Upgrade
Book Value Per Share
1.071.872.996.086.60
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).